An assay used to assess critically ill patients’ risk of developing severe sepsis or septic shock now will be available to help clinicians manage antibiotics for patients with lower respiratory tract infections or sepsis.
The FDA recently approved expanded use of the Vidas Brahms PCT Assay, which uses procalcitonin (PCT) as a biomarker to distinguish between bacterial and viral infections. High PCT levels suggest bacterial infection while low PCT levels indicate viral infection or a noninfectious cause of illness.
Voelker R. Test Aids Antibiotic Decisions. JAMA. 2017;317(13):1308. doi:10.1001/jama.2017.2685
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: